Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

ComfyCell: Novel Bionic Bioreactor for Industrial Stem and Immune Cell Manufacturing

Project description

Next generation bioreactor for stem and immune cell manufacturing processes

Stem and immune cell therapies are revolutionising treatments for diseases like cancer and autoimmune disorders. However, scaling the production of the sensitive cells needed for these therapies (such as iPSCs and NK cells) remains a challenge. Current manufacturing processes particularly struggle with the cells’ sensitivity to high shear forces limiting scale-up. Existing bioreactor technologies are ill-suited for these delicate cells. BioThrust’s ComfyCell bioreactor simulates the cells' natural environment, enabling the intensified large-scale production that the market urgently needs. The EIC-funded ComfyCell project will validate the scalability and performance of BioThrust’s ComfyCell bioreactor through pilot programmes at an industrial scale, thereby encouraging early adopters with cost-saving opportunities and valuable case studies.

Objective

Stem and immune cell therapies are transforming modern medicine, offering new treatments for conditions like cancer, neurodegenerative diseases, and autoimmune disorders. Leveraging cells such as induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), Natural Killer (NK) cells, and T-cells, these therapies hold the potential to address diseases affecting hundreds of millions worldwide. However, the inability to scale the production of these cells presents a major bottleneck in making these life-saving treatments accessible. Stem and immune cells are highly sensitive, struggling with conventional manufacturing processes due to their intolerance to high shear forces, nutrient supply fluctuations, and shifts in oxygen and pH levels.
Despite the significant medical advancements, no scalable solution currently exists for industrial production of these cells. iPSC, NK cell, and T-cell cultivation is typically limited to small volumes (2L), and existing techniques rely on outdated bioreactor technologies initially designed for more robust cells. Approaches like conventional stirred tank reactors (STRs), wave bags, and vertical wheel bioreactors introduce high shear forces or require labour-intensive reconfiguration, making them inadequate for industrial stem and immune cell manufacturing.
BioThrust’s ComfyCell bioreactor is designed to address this challenge, offering a revolutionary solution for cultivating sensitive stem and immune cells at industrial scales. As the first bioreactor to simulate the natural environment of these delicate cells, ComfyCell enables more efficient, high-yield production which is urgently desired by the market. By securing EIC Accelerator funding, BioThrust will be able to validate ComfyCell’s scalability and performance through pilot programs in industrial scales, incentivizing early adopters with cost-saving opportunities and valuable case studies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

BIOTHRUST GMBH
Net EU contribution
€ 2 496 897,00
Address
PAUWELSSTRASSE 17
52074 Aachen
Germany
SME
Yes
Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data